European Study of Cerebral Aspergillosis treated with Isavuconazole (ESCAI): A study by the ESCMID Fungal Infection Study Group
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae371 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Alexandra Serris und 15 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Infectious Diseases and Tropical Medicine, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, Universi…. Hauptthemen laut MEDLINE: Nitriles, Pyridines, Antifungal Agents, Triazoles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: NIHR, Manchester Biomedical Research Centre, Medical Research Council Centre for Medical Mycology.
Abstract (Originalsprache)
Background
Cerebral aspergillosis (CA) is associated with high mortality. According to the European Conference on Infections in Leukemia and the European Society of Clinical Microbiology and Infectious Diseases guidelines, the recommended first-line treatment for all forms of aspergillosis is voriconazole or isavuconazole. However, little is known about the efficacy and safety of isavuconazole in CA.
Methods
We conducted a European multicenter retrospective study of patients treated with isavuconazole for proven or probable CA between 2014 and 2022 and compared the outcomes with those of weighted control groups from the previously published French national cohort of CA, the Cerebral Aspergillosis Lesional Study (CEREALS).
Results
Forty patients from 10 countries were included. The main underlying conditions were hematological malignancies (53%) and solid-organ transplantation (20%). Isavuconazole was administered as a first-line treatment to 10 patients, primarily in combination therapy, resulting in control of CA in 70% of these cases. Thirty patients received isavuconazole after a median of 65 days on another therapy, mostly because of side effects (50%) or therapeutic failure (23%) of the previous treatment. Predominantly given as monotherapy, it achieved control of CA in 73% of the patients. Seventeen patients (43%) underwent neurosurgery. When measured, isavuconazole levels were low in cerebrospinal fluid but adequate in serum and brain tissue. Isavuconazole toxicity led to treatment interruption in 7.5% of the patients. Twelve-week mortality was 18%. Comparison with the CEREALS cohort showed comparable survival in patients receiving isavuconazole or voriconazole as a first-line treatment.
Conclusions
Isavuconazole appears to be a well-tolerated treatment. Mortality of CA treated with isavuconazole is similar to that reported with voriconazole.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Infectious Diseases and Tropical Medicine, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, Université de Paris, Paris, France.
- Mycology Reference Centre Manchester and Department of Infectious Diseases, Manchester Academic Health Science Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
- Division of Evolution, Infection and Genomics, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
- Infectious Diseases Department, Hospital de Braga, Braga, Portugal.
- Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
- Infectious Diseases Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.
ORCID-Profile: Alexandra Serris, Riina Rautemaa-Richardson, Anna Candoni, Carolina Garcia-Vidal, Ana Alastruey-Izquierdo, Helena Hammarström, Danila Seidel, Jan Styczynski, Raquel Sabino, Frederic Lamoth, Juergen Prattes, Fanny Lanternier
Förderung
- NIHR
- Manchester Biomedical Research Centre
- Medical Research Council Centre for Medical Mycology
- NIHR Exeter Biomedical Research Centre
Zitieren
APA
Serris, A., Rautemaa-Richardson, R., Laranjinha, J. D., Candoni, A., Garcia-Vidal, C., Alastruey-Izquierdo, A., Hammarström, H., Seidel, D., Styczynski, J., Sabino, R., Lamoth, F., Prattes, J., Warris, A., Porcher, R., Lanternier, F., & ESCAI Study Group (2024). European Study of Cerebral Aspergillosis treated with Isavuconazole (ESCAI): A study by the ESCMID Fungal Infection Study Group. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae371
Vancouver
Serris A, Rautemaa-Richardson R, Laranjinha JD, Candoni A, Garcia-Vidal C, Alastruey-Izquierdo A, et al. European Study of Cerebral Aspergillosis treated with Isavuconazole (ESCAI): A study by the ESCMID Fungal Infection Study Group. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae371
BibTeX
@article{Serris2024,
author = {Serris, Alexandra and Rautemaa-Richardson, Riina and Laranjinha, Joana D and Candoni, Anna and Garcia-Vidal, Carolina and Alastruey-Izquierdo, Ana and Hammarström, Helena and Seidel, Danila and Styczynski, Jan and Sabino, Raquel and Lamoth, Frederic and Prattes, Juergen and Warris, Adilia and Porcher, Raphaël and Lanternier, Fanny and ESCAI Study Group, ESCAI Study Group},
title = {European Study of Cerebral Aspergillosis treated with Isavuconazole (ESCAI): A study by the ESCMID Fungal Infection Study Group},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae371}
}
EUVIMED